Skip to content
PeptideAI
Animal data onlyhormone supportinflammationlongevity

Prostamax

Prostate-directed tetrapeptide taken in short courses by older men for urinary flow and prostate comfort, and the bioregulator most often used as an adjunct in chronic prostatitis protocols.

Also known as Lys-Glu-Asp-Pro, KEDP, prostate Cytogen, Prostagen, Prostamax

Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.

Preclinical rodent chronic-prostatitis work from Khavinson's institute reports reduced inflammation and better glandular architecture. There are no controlled human urological trials, no IPSS or uroflowmetry data, and no independent replication. Russian registration is as a supplement, not a drug.

How it works

Prostamax is Lys-Glu-Asp-Pro, CAS 473578-47-1, molecular formula C20H33N5O9. Russian preclinical work in chronic prostatitis models reports reduced inflammatory infiltrate, restored glandular architecture and improved secretory function. The mechanistic argument is the class-standard chromatin one, with the peptide proposed to loosen condensed chromatin in prostate and immune cells and reactivate age-silenced genes. Nothing here has been tested against IPSS scores, post-void residual volume, uroflowmetry or PSA in a controlled human trial, so the benign prostatic hyperplasia claims made for it are entirely extrapolated.

Targets: Prostate epithelium, Local inflammatory signalling, Chromatin structure

Dosing

ProtocolDoseFrequencyRoute
Research-market injectable courseAny time of day.1 mg – 2 mgonce daily for 10 to 20 dayssubcutaneous
Oral capsule courseBefore food.1 mg – 2 mgonce daily for 20 to 30 daysoral
  • · 20 mg vial at 10 mg/mL gives a complete course; this is convention, not a validated dose.
  • · Libidon is the corresponding prostate Cytomax capsule if you prefer the extract format.

Cycling

Ten to twenty days injectable or a month of capsules, repeated two to three times a year.

Work out your exact syringe units →

Pharmacology

Half-life
Not measured; a free tetrapeptide clears from plasma within minutes.
Onset
Nothing acute. Urinary symptom changes, when reported anecdotally, are described over three to four weeks.
Routes
oral, subcutaneous, intramuscular
Molecule
Synthetic tetrapeptide
Sequence length
4 amino acids
Molecular weight
487.5 Da

Handling

Diluent
Bacteriostatic water
Typical mix
2 or 3 mL
Vial sizes
20 mg
Lyophilised
Room temperature short term; fridge or freezer long term.
Reconstituted
Refrigerated, use within about 30 days.
Light sensitive
Yes — keep it out of the light

Mixing

20 mg in 2 mL gives 10 mg/mL; 1 mg is 10 units on a U-100 syringe.

Side effects

  • commonInjection-site irritation— Transient.
  • commonNo consistent systemic side effects reported— Thin exposure data.

Do not use if

  • Prostate cancer, or an unexplained rising PSA - get the diagnosis before you start masking symptoms with anything.
  • Acute urinary retention - this is a urological emergency and no peptide addresses it.
  • Not for use in women or anyone without a prostate; there is no rationale.

Combining it

  • redundantlibidon — Libidon is the prostate Cytomax extract covering the same claimed ground.
  • cautionfinasteride — No known pharmacological interaction, but combining them makes it impossible to attribute any symptom change - and finasteride is the one with outcome data.

What to monitor

  • · PSA before starting, and repeated at your normal screening interval - a peptide that alters prostate symptoms should never be allowed to delay a cancer diagnosis.
  • · An IPSS symptom score before and after each course gives you a real, comparable number.

Legal status

Not approved for human use in the US, UK or EU; sold as a research chemical in the West and as a registered supplement in Russia.

References

  • Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)
  • Khavinson, Linkova & Tarnovskaya, short peptides regulate gene expression (preclinical)

Mechanism in depth

Prostamax's verifiable literature is Georgian, biophysical, and once again not about the organ on the label. Dzhokhadze and Buadze's group in Tbilisi - the same collaboration that produced the Livagen chromatin work - reported deheterochromatinisation of chromatin in old age induced by Lys-Glu-Asp-Pro, and an earlier paper from the same circle examined the peptide's influence on heterochromatin of human lymphocytes in situ. There is also a microcalorimetric study of human blood lymphocyte cultures in the presence of copper, cadmium and prostamax, which is an unusual and rather rigorous physical technique - differential scanning microcalorimetry measures the actual thermal stability of chromatin rather than inferring it. So what has genuinely been shown is that KEDP loosens condensed chromatin in aged human lymphocytes, measured physically. That is the same finding as Livagen's, in the same laboratory, with a different peptide. It says something real about this family and nothing specific about prostate. The prostatitis and glandular architecture claims come from Russian preclinical models that I could not retrieve as discrete indexed studies, and there is a related but separate line of work on peptidergic regulation of fibroblast differentiation factors in the human prostate during cell ageing. No IPSS score, no uroflowmetry, no post-void residual volume, no PSA measurement, no prostate volume on ultrasound has ever been published for this compound in a controlled human study.

What usually goes wrong

The specific danger is diagnostic delay. Prostate cancer and benign hyperplasia produce overlapping urinary symptoms, and anything that makes a man feel his symptoms are being managed reduces the chance he gets a PSA and a digital rectal examination this year rather than in three years. Get the baseline PSA before you start anything. The second failure is untreated obstruction: chronic incomplete emptying leads to recurrent infection, bladder stones, and occasionally obstructive renal impairment, all of which are silent until they are not. Third, acute urinary retention is a same-day emergency requiring catheterisation, and no peptide has any role in it. Fourth, the compound's verified biology is chromatin decondensation in lymphocytes; the prostate label is a naming convention, and the honest expectation is that nothing urological will change.

Bloodwork worth running

MarkerWhenWhy it matters
PSA, total and freeBaseline before starting anything, then at your normal screening interval. Avoid ejaculation for 48 hours and cycling for 24 hours before the draw - both raise PSA transiently.This is the non-negotiable one. Lower urinary tract symptoms overlap between benign hyperplasia and prostate cancer, and a compound that plausibly softens symptoms without touching the underlying pathology is a compound that can delay a diagnosis. A free-to-total ratio helps discriminate benign from malignant causes of an elevated total.Act if: A total PSA above about 4 ng/mL, or a rise of more than 0.75 ng/mL per year, or a free-to-total ratio under 15 percent, means urology - not another course. Never let symptom improvement on any supplement postpone that referral.
IPSS symptom scoreBefore the course and four weeks after it ends.Not bloodwork, but it is the standardised, validated, free instrument that turns a vague sense of improvement into a comparable number. Eight questions, thirty-five points, and it is what a urologist will use.Act if: A change of fewer than three points is within noise and means nothing. A worsening score, or new hesitancy, straining or incomplete emptying, needs assessment including a post-void residual measurement.
Creatinine and eGFRBaseline and annually while symptoms persist.Chronic bladder outlet obstruction can cause obstructive uropathy and quietly damage kidneys. If someone is self-managing urinary symptoms with peptides for months, this is the test that catches the consequence.Act if: Any unexplained fall in eGFR in a man with obstructive urinary symptoms requires urgent urological assessment and a renal ultrasound.

Pharmacokinetics

Metabolism
Aminopeptidase cleavage to lysine, glutamate, aspartate and proline.
Elimination
Renal filtration of fragments.

Receptor targets

  • Condensed heterochromatin in aged human lymphocytes — No binding constant; effect characterised by cytogenetics and differential scanning microcalorimetry

    Deheterochromatinisation - physical loosening of chromatin that had condensed with age. The best-verified effect this peptide has, and it is not prostatic.

  • Prostate fibroblast differentiation signalling

    Peptidergic regulation of fibroblast differentiation factors in human prostate during cell ageing has been reported in the same programme. This is the closest thing to a prostate-specific mechanism I could verify, and it is expression-level work in culture.

  • No identified receptor — None published

    No receptor, no androgen-pathway interaction, no 5-alpha-reductase or alpha-adrenergic activity of any kind.

What to expect, and when

Nothing acute. Weeks one to three: no expected change; anecdotal reports of improved flow in the first week are almost certainly the natural day-to-day variability of lower urinary tract symptoms, which is large. Weeks three to four: the window in which users typically report symptom change, and the reason to have a written IPSS baseline rather than an impression. Four weeks post-course: repeat the IPSS. A change under three points is noise. Months: nothing established, and no compound in this class has published prostate volume or flow-rate data at any timepoint.

Stacking and comparisons

Prostamax plus Libidon is duplication - synthetic and extract for the same claim. The comparisons that matter are with drugs that work: tamsulosin or another alpha blocker improves flow within days, and finasteride or dutasteride shrink the gland over months with randomised data behind them. If you combine Prostamax with either, any improvement belongs to the drug and you will have paid for a peptide to take the credit. If you are using saw palmetto alongside it, be aware that the largest randomised trials of saw palmetto for BPH were negative, so you are stacking two things with no demonstrated benefit.

Against tamsulosin: an alpha blocker improves flow and symptom scores within days, with a well-known side-effect profile including retrograde ejaculation and orthostatic dizziness. Against finasteride and dutasteride: 5-alpha-reductase inhibitors reduce prostate volume and the risk of acute retention and surgery over years, with randomised data, at the cost of sexual side effects that some men find unacceptable. Against tadalafil 5 mg daily: approved for BPH symptoms with the side benefit of erectile function. Prostamax has none of this - no flow data, no symptom score data, no volume data. Against Libidon: the synthetic at least has defined chemistry and a verified physical effect on chromatin. Against saw palmetto: both are unproven for BPH, but saw palmetto has been through large negative randomised trials, which is more evidence than Prostamax has of any kind.

Rough cost

$35–$110/month. One 20 mg vial per injectable course, or a month of capsules. Indicative pricing, not verified against vendor listings in this session.

Genuinely uncertain

  • No controlled human urological study exists - no IPSS, no uroflowmetry, no post-void residual, no prostate volume, no PSA data.
  • The verified biology is chromatin decondensation in aged lymphocytes, not prostate tissue.
  • The Russian chronic prostatitis model work referenced in review material could not be retrieved as discrete indexed studies in this session.
  • No pharmacokinetic data of any kind by any route.
  • Whether the compound has any effect on prostate volume, androgen signalling or inflammatory infiltrate in a living man is entirely unknown.
  • Oral absorption of the intact tetrapeptide has never been demonstrated.
  • Cost figures are indicative estimates and were not verified against live vendor listings in this session.

Papers